Aptose Biosciences Inc.
Aptose Biosciences Inc. (APS.TO) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
aps.to · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Aptose Biosciences Inc. (APS.TO) measures how much investors pay for each dollar of the company's trailing earnings. APS.TO's current PE ratio of 0.79x is calculated by dividing its stock price of $2.20 by its TTM earnings per share of $2.17. −78.8% discount vs 5Y avg 3.7x
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2007 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Aptose Biosciences Inc.You APS.TO | $6M | 0.79x | — | $2.17 |
 Appili Therapeutics Inc. APLI.TO | $2M | N/A | — | -$0.02 |
 Avricore Health Inc. AVCR.V | $5M | N/A | — | -$0.02 |
 CanadaBis Capital Inc. CANB.V | $2M | N/A | — | -$0.01 |
 Restart Life Sciences Corp. HEAL.CN | $3M | N/A | — | -$0.04 |
 Kane Biotech Inc. KNE.V | $5M | N/A | — | -$0.02 |
 Mercanto Holdings Inc. MUSH.V | $6M | N/A | — | -$0.01 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-10.59 | — | |
2024-12-31 FY2024 | — | $-0.04 | — | |
2023-12-31 FY2023 | — | $-7.58 | — | |
2022-12-31 FY2022 | — | $-6.80 | — | |
2021-12-31 FY2021 | — | $-11.01 | — | |
2020-12-31 FY2020 | — | $-9.30 | — | |
2019-12-31 FY2019 | — | $-7.86 | — | |
2018-12-31 FY2018 | — | $-12.97 | — | |
2017-12-31 FY2017 | — | $-7.84 | — | |
2016-12-31 FY2016 | — | $-16.31 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Aptose Biosciences Inc. (APS.TO) measures how much investors pay for each dollar of the company's trailing earnings. APS.TO's current PE ratio of 0.79x is calculated by dividing its stock price of $2.20 by its TTM earnings per share of $2.17.
Frequently asked questions
APS.TO pe ratio · 6 questionsAPS.TO's current PE ratio is 0.79x as of 2026-06-08, based on a stock price of $2.20 and TTM EPS of $2.17. Data sourced from Financial Modeling Prep via APS.TO's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Aptose Biosciences Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08